ARGEN-X N V has a total of 18 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2009. It filed its patents most often in United States, EPO (European Patent Office) and United Kingdom. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are INHIBRX LP, PIERIS PROTEOLAB AG and INHIBRX LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 9 | |
#2 | EPO (European Patent Office) | 2 | |
#3 | United Kingdom | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Canada | 1 | |
#6 | China | 1 | |
#7 | Israel | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Chemical engineering |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Microorganisms | |
#5 | Analysing materials | |
#6 | Separation |
# | Name | Total Patents |
---|---|---|
#1 | Dreier Torsten | 9 |
#2 | De Haard Johannes Joseph Wilhelmus | 6 |
#3 | De Haard Johannes | 6 |
#4 | Ulrichts Peter | 6 |
#5 | Blanchetot Christophe | 5 |
#6 | Ongenae Nicolas G H | 4 |
#7 | Saunders Michael | 4 |
#8 | Blanchetot Christophe Frederic Jerome | 3 |
#9 | Festjens Els | 2 |
#10 | Wajant Harald | 2 |
Publication | Filing date | Title |
---|---|---|
GB201612337D0 | Ant-il-22r antibodies | |
GB201507228D0 | Antibodies to IL-24 |